NEW YORK, July 25, 2024 /PRNewswire/ — NYU Langone Well being’s Perlmutter Most cancers Middle has named Jonathan M. Gerber, MD, as its new chief medical officer. Dr. Gerber joins NYU Langone from the College of Massachusetts Chan Medical College and UMass Memorial Well being, the place he served because the director of the most cancers heart and chief of hematology and oncology.
In his new position, Dr. Gerber will work with Perlmutter Most cancers Middle (PCC) and NYU Langone management groups to determine and make sure the highest high quality of cutting-edge affected person care, efficient collaboration amongst college and workers, and the mixing of medical and translational analysis at PCC areas in Manhattan, Brooklyn, Queens, and Lengthy Island. He can even coordinate efforts throughout totally different most cancers specialties, departments, and campuses.
“I am thrilled to be becoming a member of the Perlmutter Most cancers Middle because it continues to develop and evolve,” says Dr. Gerber. “I sit up for working with colleagues throughout NYU Langone Well being to develop and innovate the world-class care at every of our areas.”
Dr. Gerber’s medical pursuits embody leukemia and associated hematologic circumstances, in addition to blood and marrow transplantation (BMT) and mobile remedy. He’s additionally a translational laboratory researcher and an early-phase medical trial investigator. His analysis focuses on enhancing the identification and focusing on of the stem cells on the root of leukemia and different hematologic ailments, with the aim of personalizing remedy and creating remedies which can be simpler and fewer poisonous.
“Dr. Gerber is a confirmed chief on the planet of most cancers care and analysis,” says Alec Kimmelman, MD, PhD, the Anita Steckler and Joseph Steckler Chair of Radiation Oncology, and the director of the Perlmutter Most cancers Middle at NYU Langone Well being. “We’re lucky to have him be part of our staff to steer our medical efforts and to make sure all of our sufferers have entry to our excellent care and state-of-the-art medical trials.”
About Dr. Gerber
Dr. Gerber acquired his BA in biology and MD at Johns Hopkins, the place he additionally accomplished his inner medication residency and hematology fellowship. Upon completion of his coaching, he served on the college of the Johns Hopkins College of Medication and Johns Hopkins Hospital for 5 years within the Division of Hematology. From there, he joined the Levine Most cancers Institute (LCI) because the founding director of its Leukemia Division. Whereas at LCI, he helped launch the BMT Program, performing the primary allogeneic BMT in an grownup in Charlotte, NC, in 2014. In 2018, he was then recruited to be the chief of hematology and oncology and medical director of the most cancers service line on the College of Massachusetts Chan Medical College and UMass Memorial Well being, the place he was subsequently promoted to the director of the most cancers heart.
Dr. Gerber has co-authored over 50 articles in outstanding publications and has introduced analysis findings at nationwide and worldwide conferences, in addition to serving as a reviewer for the Nationwide Institutes of Well being and prime journals within the area. He’s additionally a member of the editorial board and the affiliate editor for hematology content material for HemOnc At the moment. Dr. Gerber was a member of the staff that acquired a 2023 Prime 10 Scientific Analysis Achievement Award from the Scientific Analysis Discussion board for its work on the therapy of COVID-19 with convalescent plasma, which was printed in The New England Journal of Medication. His leukemia analysis has resulted in three US patents and has been translated into medical trials.
Dr. Gerber can also be an energetic member of a number of skilled societies, together with the American Society of Hematology (ASH) and the American Society of Scientific Oncology (ASCO). At the moment, he’s a member of the ASH Committee on Apply and the liaison to the ASH Subcommittee on Precision Medication, as a effectively as a member of the ASH Persevering with Certification Working Group. He beforehand served on the ASCO Most cancers Analysis and Training committees. Dr. Gerber has additionally served on the boards of the Charlotte and the New England chapters of the Leukemia & Lymphoma Society. As well as, he was a member of the Massachusetts Division of Public Well being’s Prognosis and Remedy Working Group for the 2024-2029 State Most cancers Plan.
Media Contact:
Ryan Dziuba
Media Relations Supervisor
[email protected]
212-404-4131
SOURCE NYU Langone Well being
